Many patients with rectal cancer may not need chemoradiotherapy

It's unclear whether all patients with advanced rectal cancer need chemoradiotherapy, or whether some can forego the treatment and therefore be spared its side effects. A new BJS (British Journal of Surgery) study found that patients who are not at high risk of local recurrence can safely undergo surgery without receiving chemoradiotherapy. Investigators estimate that this strategy could reduce the number of patients who receive chemoradiotherapy by roughly half, with only a minimal risk of undertreatment.

In the observational trial, 545 patients with cancer of the rectum were stratified into low-and high-risk groups. Chemoradiotherapy was administered to patients at and was avoided in 42% of patients. The 3- and 5-year local recurrence rates of cancer were similarly low in patients who had surgery alone (a procedure called total mesorectal excision) versus who received chemoradiotherapy followed by surgery.

"The results are an important step to an individualized therapy of rectal ," said co-author Prof. Theodor Junginger, of the University Medical Centre Mainz, in Germany. "The concept avoids adverse effects of chemoradiotherapy, shortens duration of treatment, and saves costs."


Explore further

Reducing Tx may harm safety in early HPV+ oropharyngeal cancer

More information: R. Ruppert et al, Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial, British Journal of Surgery (2018). DOI: 10.1002/bjs.10879
Provided by Wiley
Citation: Many patients with rectal cancer may not need chemoradiotherapy (2018, May 11) retrieved 21 February 2019 from https://medicalxpress.com/news/2018-05-patients-rectal-cancer-chemoradiotherapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more